Researchers have developed a novel digital cognitive testing platform, using the Oxford Cognitive Testing Portal, that correlates with serological biomarkers to accurately measure cognitive impairment in Alzheimer’s patients. The study highlights the platform’s effectiveness in capturing subtle signs of impairment, potentially revolutionizing early diagnosis and tracking of Alzheimer’s disease.
Opinion | Farm-to-Hospital Meals Can Help Protect Patients and the Climate
Schettler is an advisor for health and climate organizations, and a former emergency physician. Sirois is the director of an international non-governmental organization (NGO) working